Article
'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility.
Cancer letters - 28 Apr 2005
Belogubova Evgeniya V, Kuligina Ekatherina Sh, Togo Alexandr V, Karpova Maria B, Ulibina Julia M, Shutkin Vladimir A, Hanson Kaido P, Popowski Katrin, Mosyagin Igor, Cascorbi Ingolf, Hirvonen Ari, Imyanitov Evgeny N
Abstract excerpt
NAT2 (arylamine N-acetyltransferase 2) polymorphism, being a key determinant of individual variations in acetylation capacity, is suspected to modify the risk of carcinogen-related malignancies. As tobacco smoke and other inhaled hazards contain a variety of NAT2 substrates, the relationship between NAT2 phenotype and lung cancer (LC) risk has been a subject of intensive research, however different case-control...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
